NCT05573126 2026-03-20Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerEllipses PharmaPhase 1/2 Recruiting95 enrolled